市場調查報告書

新藥物遞輸系統(NDDS)的全球市場:各給藥途徑、NDDS的方式、地區 - 成長,趨勢,及預測(2018年∼2023年)

Novel Drug Delivery Systems (NDDS) Market - Segmented by Route of Administration, Mode of NDDS, Geography - Growth, Trends, and Forecast (2018 - 2023)

出版商 Mordor Intelligence LLP 商品編碼 390732
出版日期 內容資訊 英文 141 Pages
商品交期: 2-3個工作天內
價格
新藥物遞輸系統(NDDS)的全球市場:各給藥途徑、NDDS的方式、地區 - 成長,趨勢,及預測(2018年∼2023年) Novel Drug Delivery Systems (NDDS) Market - Segmented by Route of Administration, Mode of NDDS, Geography - Growth, Trends, and Forecast (2018 - 2023)
出版日期: 2019年01月01日內容資訊: 英文 141 Pages
簡介

全球新藥物遞輸系統市場在2018年∼2023年間,預測將以2.9%的年複合成長率成長。

本報告提供全球新藥物遞輸系統市場的相關調查,市場機會和課題,成長及阻礙因素,各給藥途徑、NDDS的方式、地區的市場分析,競爭情形,主要企業的簡介等資訊。

目錄

第1章 簡介

  • 市場定義

第2章 調查方法

第3章 摘要整理

第4章 主要推論

第5章 市場概要

  • 目前市場方案
  • 波特的五力分析
    • 供應商談判力
    • 消費者談判力
    • 新加入廠商的威脅
    • 替代產品及服務的威脅
    • 產業內的競爭

第6章 成長及阻礙因素,機會,課題分析(DROC)

  • 成長要素
    • 藥物的控制放出的必要條件
    • 藥理學的進步促進新藥物輸送系統(NDDS)的採用增加
    • 促進NDDS的開發的技術進步
  • 阻礙因素
    • 嚴格的法規指南
    • 產品回收
    • 穩定性的問題
  • 市場機會
  • 主要課題

第7章 市場區隔

  • 各給藥途徑
    • 口服
    • 注射
    • 經皮
    • 其他
  • NDDS的各模式
    • 標的
    • 控制
    • 調變
  • 各地區
    • 北美
    • 歐洲
    • 亞太地區
    • 中東、非洲
    • 南美

第8章 競爭情形

  • M&A分析
  • 契約,合作,及聯盟
  • 新產品的銷售

第9章 企業簡介

  • Abbott Laboratories
  • AstraZeneca PLC
  • Bayer Healthcare Pharmaceuticals
  • GlaxoSmithKline PLC
  • Johnson & Johnson
  • Merck & Co.
  • Novartis AG
  • Pfizer Inc.
  • Roche Holding A
  • Sanofi SA

第10章 市場今後展望

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: 51066

The novel drug delivery systems market is expected to witness a CAGR of 2.9%, during the forecast period, 2018-2023. There is a continuous growth in the market of drug delivery systems and is forecasted to continue to grow at an impressive rate in future also.

Requirement of Controlled Release of Drugs

The method by which a drug is being delivered can have significant influence on its efficacy. Many of the drugs have an optimum concentration range and requirement of controlled release of drugs in the body has to be there. The concentrations above or below the concentration range can be toxic or can produce no therapeutic benefits at all. Transdermal patches, implants, nasal systems, microcapsules, etc. are some of the common systems that are considered under the controlled release systems. Hence, the requirement of controlled release of drugs leads to drive the novel drug delivery systems market.

The other factors include advancement in pharmacology promoting increased adoption of novel drug delivery systems (NDDS) and technological advancements promoting development of NDDS.

Stability Issues with the NDDS System

The stability of the delivery system is one of the most important factors, which effects the drug delivery systems market. Liposomes are the most common nanocarriers for drug delivery owing to the several advantages they offer over other delivery systems. Liposomes help in stabilizing therapeutic compounds and improved biodistribution of compounds to target sites in vivo. However, stability of liposome-based drug delivery systems is a major concern, which is restraining the growth of this market.

The other restraining factors also include the stringent regulatory guidelines and product recalls.

North America Dominates the Market

North America has dominated the novel drug delivery systems in cancer therapy market in 2016 with a revenue share of around 37%. North America holds the major share in the market owing to the factors, such as growing R&D in the field of drug delivery systems, the high adoption rate of new technologies, and supportive reimbursement policies. Asia Pacific is also expected to witness growth in the novel drug delivery systems market in the upcoming future.

Key Developments in the Market

  • November 2017: Juluca (dolutegravir and rilpivirine) approved in US as first 2-drug regimen, once-daily, single pill a complete regimen for the maintenance treatment of virologically suppressed HIV-1 infection

The major players include - Abbott Laboratories, AstraZeneca PLC, Bayer Healthcare Pharmaceuticals, GlaxoSmithKline PLC, Johnson & Johnson, Merck & Co., Novartis AG, Pfizer Inc., Roche Holding AG and Sanofi SA, among others.

Reasons to Purchase this Report:

  • Current and future novel drug delivery systems market outlook in the developed and emerging markets
  • Analyzing various perspectives of the market with the help of Porter's five forces analysis
  • The segment that is expected to dominate the market
  • Regions that are expected to witness fastest growth during the forecast period
  • Identify the latest developments, market shares, and strategies employed by the major market players
  • 3-month analyst support, along with the Market Estimate sheet (in excel)

Customization of the Report:

  • This report can be customized to meet your requirements. Please connect with our analyst, who will ensure you get a report that suits your needs

Table of Contents

1. Introduction

  • 1.1 Market Definition

2. Research Methodology

3. Executive Summary

4. Key Inferences

5. Market Overview

  • 5.1 Current Market Scenario
  • 5.2 Porter's Five Forces Analysis
    • 5.2.1 Bargaining Power of Suppliers
    • 5.2.2 Bargaining Power of Consumers
    • 5.2.3 Threat of New Entrants
    • 5.2.4 Threat of Substitute Product and Services
    • 5.2.5 Competitive Rivalry Within the Industry

6. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)

  • 6.1 Market Drivers
    • 6.1.1 Requirement of Controlled Release of Drugs
    • 6.1.2 Advancement in Pharmacology Promoting Increased Adoption of Novel Drug Delivery Systems (NDDS)
    • 6.1.3 Technological Advancements Promoting Development of NDDS
  • 6.2 Market Restraints
    • 6.2.1 Stringent Regulatory Guidelines
    • 6.2.2 Product Recalls
    • 6.2.3 Stability Issues
  • 6.3 Opportunities
  • 6.4 Key Challenges

7. Market Segmentation

  • 7.1 By Route of Administration
    • 7.1.1 Oral Drug Delivery Systems
    • 7.1.2 Injectable Drug Delivery Systems
    • 7.1.3 Pulmonary Drug Delivery Systems
    • 7.1.4 Transdermal Drug Delivery Systems
    • 7.1.5 Others
  • 7.2 By Mode of NDDS
    • 7.2.1 Targeted Drug Delivery Systems
    • 7.2.2 Controlled Drug Delivery Systems
    • 7.2.3 Modulated Drug Delivery Systems
  • 7.3 By Geography
    • 7.3.1 North America
      • 7.3.1.1 United States
      • 7.3.1.2 Canada
      • 7.3.1.3 Mexico
    • 7.3.2 Europe
      • 7.3.2.1 France
      • 7.3.2.2 Germany
      • 7.3.2.3 United Kingdom
      • 7.3.2.4 Italy
      • 7.3.2.5 Spain
      • 7.3.2.6 Rest of Europe
    • 7.3.3 Asia-Pacific
      • 7.3.3.1 China
      • 7.3.3.2 Japan
      • 7.3.3.3 India
      • 7.3.3.4 Australia & New Zealand
      • 7.3.3.5 South Korea
      • 7.3.3.6 Rest of Asia-Pacific
    • 7.3.4 Middle East & Africa
      • 7.3.4.1 GCC
      • 7.3.4.2 South Africa
      • 7.3.4.3 Rest of the Middle East & Africa
    • 7.3.5 South America
      • 7.3.5.1 Brazil
      • 7.3.5.2 Argentina
      • 7.3.5.3 Rest of South America

8. Competitive Landscape

  • 8.1 Mergers & Acquisition Analysis
  • 8.2 Agreements, Collaborations, and Partnerships
  • 8.3 New Products Launches

9. Key Players

  • 9.1 Abbott Laboratories
  • 9.2 AstraZeneca PLC
  • 9.3 Bayer Healthcare Pharmaceuticals
  • 9.4 GlaxoSmithKline PLC
  • 9.5 Johnson & Johnson
  • 9.6 Merck & Co.
  • 9.7 Novartis AG
  • 9.8 Pfizer Inc.
  • 9.9 Roche Holding A
  • 9.10 Sanofi SA

*List Not Exhaustive

10. Future of The Market